NASDAQ$NKGN
Nkgen Biotech Inc · Q1 2025 earnings
Q1 2025 earnings · · Investor relations
Briefing
NKGen Biotech reported Q1 2025, revenue of $8.5M, net loss of $15.3M.
For Q1 2025, NKGen Biotech reported revenue of $8.5M, a net loss of $15.3M. Management discusses segment performance, capital allocation, and outlook in the earnings filing.
- Revenue $8.5M.
- Net loss $15.3M.
- NKGen Biotech highlights liquidity, operations, and 2026 priorities.
Headline financials
Revenue & EPS history
Nkgen Biotech · Revenue · Quarterly
$0
Forward guidance
The release discusses NKGen Biotech's outlook for upcoming periods, including capital allocation, operating priorities, and market risks, without relying solely on numeric EPS bridges.
Tailwinds
- NKGen Biotech cites operational execution and demand trends supporting the outlook.
- Balance sheet and liquidity actions aim to fund growth and returns.
Headwinds
- GAAP profitability remained under pressure in Q1 2025.
- Macro, pricing, and input-cost volatility could pressure margins.
- Segment mix and one-time items may affect quarter-to-quarter comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q1 2025
+6.0%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+2.7%
Avg return
30 days after
41%
7 / 17 earnings
Positive
+57.1%
Q1 2024
Best reaction
-16.9%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | +0.0% | +0.0% | +0.0% | |
| Q1 2025 | +0.0% | +0.0% | +0.0% | |
| Q2 2025 | +0.0% | +0.0% | +85.0% | |
| Q4 2024 | +21.4% | +0.0% | -5.0% | |
| Q3 2024 | +36.1% | +4.7% | -5.8% | |
| Q2 2024 | -0.8% | -37.1% | -64.1% | |
| Q1 2024 | +57.1% | +26.8% | +6.3% | |
| Q4 2023 | -16.9% | -10.8% | -8.9% | |
| Q3 2023 | +5.1% | +2.6% | +37.9% | |
| Q2 2023 | +0.3% | +0.8% | -2.9% | |
| Q1 2023 | +0.3% | -0.3% | +0.0% | |
| Q4 2022 | +0.3% | -0.3% | +0.0% | |
| Q3 2022 | -0.3% | +0.3% | +0.5% | |
| Q2 2022 | +0.0% | +0.0% | -0.1% | |
| Q1 2022 | +0.0% | +0.3% | +0.7% | |
| Q4 2021 | +0.0% | +0.3% | +0.7% | |
| Q3 2021 | +0.0% | +0.2% | +1.0% | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro